IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1246 
Small font sizeDefault font sizeIncrease font size
Read this article


    Article Cited by others


The role of peroxisome proliferator-activated receptors in human disease

Javiya V A, Patel J A

Year : 2006| Volume: 38| Issue : 4 | Page no: 243-253

   This article has been cited by
1 Thiazolidine-2,4-dione Derivatives: Programmed Chemical Weapons for Key Protein Targets of Various Pathological Conditions
Navriti Chadha,Malkeet Singh Bahia,Maninder Kaur,Om Silakari
Bioorganic & Medicinal Chemistry. 2015;
[Pubmed]  [Google Scholar] [DOI]
2 Models for the prediction of PPARs agonistic activity of indanylacetic acids
Rohit Dutt,A. K. Madan
Medicinal Chemistry Research. 2013; 22(7): 3213
[Pubmed]  [Google Scholar] [DOI]
3 The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists
Azadeh Matin,Munikumar Reddy Doddareddy,Navnath Gavande,Srinivas Nammi,Paul W. Groundwater,Rebecca H. Roubin,David E. Hibbs
Bioorganic & Medicinal Chemistry. 2013; 21(3): 766
[Pubmed]  [Google Scholar] [DOI]
4 Thiazolidine-2,4-diones: Progress towards multifarious applications
Viral S. Jain,Dhagash K. Vora,C.S. Ramaa
Bioorganic & Medicinal Chemistry. 2013; 21(7): 1599
[Pubmed]  [Google Scholar] [DOI]
5 Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions
Balakumar, P., Kaur, T., Singh, M.
Toxicology. 2008; 245((1-2)): 49-64
[Pubmed]  [Google Scholar]
6 Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions
Pitchai Balakumar,Tajpreet Kaur,Manjeet Singh
Toxicology. 2008; 245(1-2): 49
[Pubmed]  [Google Scholar] [DOI]
7 PPAR Ligands: Are They Potential Agents for Cardiovascular Disorders?
Pitchai Balakumar,Madhankumar Rose,Manjeet Singh
Pharmacology. 2007; 80(1): 1
[Pubmed]  [Google Scholar] [DOI]
8 Peroxisome Proliferator Activated Receptor Agonists: Emerging Therapy for Cardiovascular Complications
Pitchai Balakumar ., Madhankumar Rose ., Manjeet Singh .
Journal of Pharmacology and Toxicology. 2007; 2(3): 205
[HTML Full text]  [Google Scholar] [DOI]
9 PPAR dual agonists: Are they opening Pandoraśs Box?
Balakumar, P., Rose, M., Ganti, S.S., Krishan, P., Singh, M.
Pharmacological Research. 2007; 56(2): 91-98
[Pubmed]  [Google Scholar]
10 PPAR ligands: Are they potential agents for cardiovascular disorders?
Balakumar, P., Rose, M., Singh, M.
Pharmacology. 2007; 80(1): 1-10
[Pubmed]  [Google Scholar]
11 Evolution of peroxisome proliferator-activated receptor agonists
Chang, F., Jaber, L.A., Berlie, H.D., OśConnell, M.B.
Annals of Pharmacotherapy. 2007; 41(6): 973-983
[Pubmed]  [Google Scholar]
12 Prevention of type 2 diabetes mellitus - Current opportunities
Zełobowska, K., Gumprecht, J., Simońska-Cichocka, E., Zywiec, J., Skubala, A., Grzeszczak, W.
Diabetologia Doswiadczalna i Kliniczna. 2007; 7(4): 161-167
[Pubmed]  [Google Scholar]
13 Rhodanine derivatives as novel peroxisome proliferator-activated receptor γ agonists
Liu, Q., Zhang, Y.-Y., Lu, H.-L., Li, Q.-Y., Zhou, C.-H., Wang, M.-W.
Acta Pharmacologica Sinica. 2007; 28(12): 2033-2039
[Pubmed]  [Google Scholar]
14 PPARs, metabolic syndrome and cancer
Tang, C.-C., Chieh, K., Chen, T.-S., Hsu, S.-Y.
Journal of Internal Medicine of Taiwan. 2007; 18(5): 244-255
[Pubmed]  [Google Scholar]


Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow